Employees: 3,236
Size McBride (MCB.L) is a United Kingdom Consumer Staples company (Household/Personal Care) with a market value of $377M, the 325th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £175.80 on 18 Nov 2026.
Performance Over six months the shares gained 7.5%, against -16.6% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 0.8% over the last twelve months (peer median +8.9%); the operating margin is 6.2% (peer median 8.2%).
Valuation It trades at 8.4× forward earnings against a peer median of 20.1× (cheapest of 17).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.3 points above its cost of capital (10.2% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | £934M | £934M | £926M | £935M | £889M |
| Revenue growth | — | +1% | -1% | +5% | — |
| Gross profit | £343M | £343M | £340M | £346M | £261M |
| EBITDA | £80.1M | £80.4M | £85.1M | £92.2M | £34.0M |
| Net income | £30.0M | £30.0M | £33.2M | £33.3M | -£11.5M |
| Free cash flow | £13.4M | £13.4M | £43.1M | £44.9M | £800,000 |
| Capital expenditure | £31.2M | £31.2M | £30.4M | £19.6M | £12.0M |
| Total debt | n/a | £188M | £139M | £141M | £168M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MCB.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.1% | -9.5% | 8th highest of 21 |
| 6-month return | +7.5% | -16.6% | 7th highest of 21 |
| Distance from 52-week high | -17.9% | -38.0% | 5th highest of 21 |
| Revenue growth (TTM) | +0.8% | +8.9% | 5th lowest of 21 |
| Operating margin | 6.2% | 8.2% | 10th lowest of 21 |
| Forward P/E | 8.4× | 20.1× | cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | -0.7% | 2.8% | 6th least demanding of 15 |
| Growth delivered (Del g) | +6.5% | +6.2% | 7th highest of 15 |
| Hurdle (Req g minus delivered) | -7.2 pp | -3.9 pp | 6th least demanding of 15 |
| ROIC minus cost of capital | +8.3 pp | +1.4 pp | 6th highest of 21 |
| EV / EBITDA | 5.1× | 10.7× | 2nd cheapest of 9 |
| Net debt / EBITDA | 1.5× | -1.2× | most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| McBride MCB.L | United Kingdom | $377M | +7% | +1% | 6% | 8.4× | -0.7% | +6.5% |
| Liuzhou Liangmianzhen 600249.SS | China | $379M | -19% | -11% | -7% | n/a | n/a | n/a |
| Jinglv Environment Science & Technology 001230.SZ | China | $392M | -25% | +28% | 11% | 13.9× | n/a | n/a |
| Lafang China 603630.SS | China | $414M | -19% | +5% | 3% | 37.6× | n/a | n/a |
| Tianjin Yiyi Hygiene Products 001206.SZ | China | $429M | -15% | -8% | 9% | 19.9× | 1.9% | +6.3% |
| Hangzhou Coco Healthcare Products 301009.SZ | China | $316M | -26% | +10% | 0% | 110.7× | n/a | n/a |
| Qingdao Kingking Applied Chemistry 002094.SZ | China | $454M | -26% | +3% | 4% | n/a | n/a | n/a |
| Shandong Hiking International 600735.SS | China | $309M | -28% | -11% | -2% | n/a | -7.5% | +1.5% |
| PZ Cussons PZC.L | United Kingdom | $527M | +13% | +5% | 11% | 12.7× | -2.3% | -2.1% |
| Bajaj Consumer Care BAJAJCON.NS | India | $560M | -24% | +29% | 22% | 19.7× | 14.8% | +5.0% |
| Hangzhou Haoyue Personal Care 605009.SS | China | $726M | -18% | +10% | 6% | 17.7× | 4.4% | +7.7% |
| Milbon 4919.T | Japan | $743M | +48% | +8% | 14% | 25.7× | -3.3% | +8.2% |
| Jyothy Labs JYOTHYLAB.NS | India | $762M | -9% | +5% | 8% | 40.8× | 34.5% | +8.9% |
| SYoung 300740.SZ | China | $816M | -48% | +14% | 3% | 33.4× | 14.0% | +6.1% |
| Galaxy Surfactants GALAXYSURF.NS | India | $845M | +22% | +30% | 9% | 17.6× | 18.5% | +13.7% |
| Cosmecca Korea 241710.KS | South Korea | $847M | +23% | +42% | 12% | 16.3× | n/a | n/a |
| PSC DM0.SI | Singapore | $163M | -14% | +2% | 6% | n/a | -16.3% | +0.2% |
| Dencare (Chongqing) Oral Care 001328.SZ | China | $912M | +13% | +10% | 11% | 27.9× | 3.7% | +10.8% |
| Runben Biotechnology 603193.SS | China | $918M | -30% | +13% | 21% | 18.5× | 1.5% | +28.4% |
| Tongling Jieya Biologic Technology 301108.SZ | China | $933M | +56% | +24% | 5% | 52.5× | 28.5% | +0.8% |
| Noevir 4928.T | Japan | $978M | +7% | -3% | 28% | 20.4× | -12.8% | +4.1% |